FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
August 07, 2017 16:50 ET
|
FibroGen, Inc.
Meets Primary Endpoint with Statistical Significance Management to discuss results on today’s quarterly financial results conference call SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen,...